Safety and efficacy of omarigliptin (MK-3102), a novel Once-Weekly DPP-4 Inhibitor for the treatment of patients with type 2 diabetes

Diabetes Care

Volumn 38, Issue 11, 2015, Pages 2106-2114

  Sheu, Wayne H H ^a   Gantz, Ira ^b   Chen, Menghui ^b   Suryawanshi, Shailaja ^b   Mirza, Arpana ^b   Goldstein, Barry J ^b   Kaufman, Keith D ^b   Engel, Samuel S ^b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; METFORMIN; OMARIGLIPTIN; PIOGLITAZONE; PLACEBO; 2-(2,5-DIFLUOROPHENYL)-5-(2-(METHYLSULFONYL)-2,6-DIHYDROPYRROLO(3,4-C)PYRAZOL-5(4H)-YL)TETRAHYDRO-2H-PYRAN-3-AMINE; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; FUSED HETEROCYCLIC RINGS; GLUCOSE BLOOD LEVEL; PYRAN DERIVATIVE;

ADULT; AGED; ARTICLE; BODY WEIGHT; CHRONIC PANCREATITIS; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; FASTING PLASMA GLUCOSE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPTIMAL DRUG DOSE; PANCREAS CANCER; POSTMEAL GLUCOSE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; MIDDLE AGED; TREATMENT OUTCOME;

AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HETEROCYCLIC COMPOUNDS, 2-RING; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PYRANS; TREATMENT OUTCOME;

EID: 84962439676     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc15-0109     Document Type: Article

References (23)

1. Pratley RE, Salsali A. Inhibition of DPP-4: A new therapeutic approach for the treatment of type 2 diabetes. Curr Med Res Opin 2007;23:919-931.
2. Gallwitz B. Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes. Diabetes Metab Syndr Obes 2013;6:1-9.
3. Kania DS, Gonzalvo JD, Weber ZA. Saxagliptin: A clinical review in the treatment of type 2 diabetes mellitus. Clin Ther 2011;33:1005-1022.
4. Forst T, Bramlage P. Vildagliptin, a DPP-4 inhibitor for the twice-daily treatment of type 2 diabetes mellitus with or without metformin. Expert Opin Pharmacother 2014;15:1299-1313.
5. Said S, Nwosu AC, Mukherjee D, Hernandez GT. Alogliptin; a review of a new dipeptidyl peptidase-4 (DPP-4) inhibitor for the treatment of type 2 diabetes mellitus. Cardiovasc Hematol Disord Drug Targets 2014;14:64-70.
6. Plosker GL. Sitagliptin: A review of its use in patients with type 2 diabetes mellitus. Drugs 2014;74:223-242.
7. Biftu T, Sinha-Roy R, Chen P, et al. Omarigliptin (MK-3102): A novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes. J Med Chem 2014;57:3205-3212.
8. Kirkman MS, Rowan-Martin MT, Levin R, et al. Determinants of adherence to diabetes medications: findings from a large pharmacy claims database. Diabetes Care 2015;38:604- 609.
9. Tunceli K, Zhao C, Davies MJ, et al. Factors associatedwith adherence to oral antihyperglycemic monotherapy in patients with type 2 diabetes. Patient Prefer Adherence 2015;9:191-197.
10. Hauber AB, Tunceli K, Yang JC, et al. A survey of patient preferences for oral antihyperglycemic therapy in patients with type 2 diabetes mellitus. Diabetes Ther 2015;6:75-84.
11. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D; Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med 1999;130:461-470.
12. Liang KY, Zeger SL. Longitudinal data analysis of continuous and discrete responses for prepost designs. Indian J Stat 2000;62:134-148.
13. Tamhane AC, Hochberg Y, Dunnett CW. Multiple test procedures for dose finding. Biometrics 1996;52:21-37.
14. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med 1985;4:213-226.
15. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE; Sitagliptin Study 021 Group. Effect of the dipeptidyl peptidase- 4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006;29:2632-2637.
16. Raz I, Hanefeld M, Xu L, Caria C, Williams- Herman D, Khatami H; Sitagliptin Study 023 Group. Efficacy and safety of the dipeptidyl peptidase- 4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006;49:2564-2571.
17. Herman GA, Bergman A, Stevens C, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 2006;91:4612-4619.
18. Tatosian DA, Guo Y, Schaeffer AK, et al.Dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes treated with saxagliptin, sitagliptin, or vildagliptin. Diabetes Ther 2013;4:431-442.
19. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-865.
20. Williams-Herman D, Johnson J, Teng R, et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes Obes Metab 2010; 12:442-451.
21. Kahn SE, Haffner SM, Heise MA, et al.; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-2443.
22. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.
23. Cahn A, Raz I. Emerging gliptins for type 2 diabetes. Expert Opin Emerg Drugs 2013;18: 245-258.